1 2 3 4 UNITED STATES DISTRICT COURT 5 NORTHERN DISTRICT OF CALIFORNIA 6 SAN JOSE DIVISION 7 8 CARL ZEISS X-RAY MICROSCOPY, Case No. 5:21-cv-01129-EJD INC., 9 ORDER REGARDING MOTIONS IN Plaintiff, LIMINE 10 v. 11 Re: ECF Nos. 285, 286, 296, 297, 300 SIGRAY, INC., 12 Defendant.
13 14 In advance of the Pretrial Conference scheduled for August 7, 2025, the Court issues the 15 below order regarding some of the pending motions in limine (“MIL”) to guide the discussion. 16 The parties should be prepared to discuss the remaining MILs at the Pretrial Conference: 17 • Sigray’s MIL No. 1 (ECF No. 284) 18 • Sigray’s MIL No. 4 (ECF No. 287) 19 • Zeiss’s MIL No. 1 (ECF No. 290) 20 • Zeiss’s MIL No. 2 (ECF No. 294) 21 • Zeiss’s MIL No. 5 (ECF No. 299) 22 I. SIGRAY’S MOTIONS IN LIMINE 23 A. MIL No. 2 to Exclude Evidence or Argument Regarding Three Former Xradia/Zeiss Employees 24 Sigray moves to preclude Zeiss from introducing evidence or argument regarding Sigray’s 25 hiring of three former Xradia/Zeiss employees (the “Former Employees”). ECF No. 283-3. 26 Zeiss’s amended complaint alleges that Sigray recruited from Zeiss several employees, including 27 1 the Former Employees, who had previously worked at Xradia. Sigray argues that, aside from that 2 allegation, Zeiss has neither contended nor acquired evidence that the Former Employees had any 3 part in the alleged trade secret misappropriation. Zeiss counters that evidence concerning the 4 Former Employees is relevant to its trade secret misappropriation, unfair competition, and willful 5 patent infringement claims. ECF No. 322-1. 6 The Court DENIES Sigray’s MIL No. 2. The past employment of the Former Employees 7 by Xradia and Zeiss is probative of Sigray’s access to Zeiss’s confidential information, whether 8 Sigray unfairly competed with Zeiss by gaining access to that confidential information, and 9 Sigray’s knowledge of Zeiss’s patents. Sigray has not shown that the anticipated evidence and 10 argument will overly prejudice or mislead the jury, especially given their relevance to the claims 11 and defenses in this case. To the extent Sigray still believes that the evidence Zeiss presents at 12 trial concerning the Former Employees is irrelevant to the merits of this case, Sigray may object 13 when such evidence is presented. 14 B. MIL No. 3 to Exclude Evidence or Argument of Financial Remedies Other Than Lost Profits 15 Sigray moves to preclude Zeiss from introducing evidence or argument regarding financial 16 remedies other than lost profits. ECF No. 283-4. Sigray claims that Zeiss failed to disclose the 17 calculation of reasonable royalty or unjust enrichment damages—including in Zeiss’s expert 18 reports—so Zeiss should not be allowed to pursue these remedies at trial. Zeiss appears to 19 concede that it will not pursue unjust enrichment damages but argues that it is statutorily entitled 20 to present evidence regarding a reasonable royalty as a floor for damages pursuant to 35 U.S.C. § 21 284. ECF No. 309. 22 The Court GRANTS IN PART and DENIES IN PART Sigray’s MIL No. 3. Zeiss does 23 not oppose the MIL as to unjust enrichment damages, so it may not pursue that remedy at trial. 24 However, Zeiss may present evidence concerning a reasonable royalty. The Federal Circuit has 25 made clear that, when infringement is found, courts must award at least reasonable royalty 26 damages. Dow Chem. Co. v. Mee Indus., Inc., 341 F.3d 1370, 1381 (Fed. Cir. 2003). 27 1 Accordingly, even if the jury rejects Zeiss’s expert testimony on lost profits, the jury may still 2 consider the evidence presented to determine damages on a reasonable royalty basis. To that end, 3 the parties shall meet and confer as to what kind of reasonable royalty evidence Zeiss intends to 4 use and how it will be presented. 5 II. ZEISS’S MOTIONS IN LIMINE 6 A. MIL No. 3 to Exclude Witness Testimony Regarding Non-Infringing Alternatives 7 Zeiss seeks to preclude (1) lay witness testimony, including that of Ms. Sylvia Lewis, 8 regarding non-infringing alternatives, and (2) testimony by Sigray’s damages expert, David 9 Hanson, regarding an allegedly non-infringing alternative to the accused Eclipse product called the 10 “No Sample Y Motion Redesign.” ECF No. 295-3. Zeiss argues that, as a lay witness, Lewis may 11 not testify as to whether any alleged alternative is non-infringing. ECF No. 314-2. Zeiss also 12 contends that Hanson’s opinion concerning the No Sample Y Motion Redesign lacks foundation 13 because he relied on a conversation he had with Lewis and is untimely because he could have 14 disclosed the No Sample Y Motion Redesign earlier. Id. 15 The Court DENIES Zeiss’s MIL No. 3. Lewis may testify about the structure, operation, 16 and implementation of the No Sample Y Motion Redesign. As Sigray’s president, Lewis is 17 competent to testify about these facts because Sigray sells its Apex device, which already 18 implements the No Sample Y Motion Redesign. However, Lewis may not go further to opine that 19 the No Sample Y Motion Redesign does not infringe the patents at issue in this case. See Fed. R. 20 Evid. 701. 21 The Court will also allow Hanson to testify that the No Sample Y Motion Redesign is a 22 non-infringing alternative. Hanson’s disclosure of the No Sample Y Motion Redesign was timely 23 because Sigray’s Eclipse product was not a part of this case until a few months prior to the 24 disclosure. In 2023, Zeiss’s technical and damages expert reports only addressed Sigray’s 25 TriLambda and Prisma products. Zeiss began accusing the Eclipse product in February 2025, 26 when Zeiss served supplemental expert reports. Hanson responded to those supplemental reports 27 1 with his own report in May 2025, in which he opined that the No Sample Y Motion Redesign is a 2 non-infringing alternative to the Eclipse product. Furthermore, Hanson’s opinion does not lack 3 foundation. He may properly rely on testimony from lay witnesses, like Lewis, to form his 4 opinions. See Fed. R. Evid. 703 (“[an] expert may base an opinion on facts or data in the case that 5 the expert has been made aware of or personally observed.”). To the extent Zeiss contests the 6 weight and basis of Hanson’s opinion, Zeiss may cross examine Hanson at trial. 7 B. MIL No. 4 to Exclude Evidence or Argument Regarding Post-Grant Proceedings 8 Zeiss moves to exclude evidence, testimony, and argument regarding any post-grant 9 proceedings, including inter partes review and ex parte reexamination, on the patents asserted in 10 this case. ECF No. 297. Zeiss argues that these post-grant proceedings are irrelevant because 11 invalidity is no longer an issue in this litigation. Further, Zeiss contends that such evidence will 12 confuse the jury and waste time, because the parties will be required to explain and contextualize 13 the post-grant proceedings to the jury. Sigray opposes Zeiss’s motion and claims that the post- 14 grant proceedings are highly probative of whether Sigray infringed Zeiss’s patents willfully. ECF 15 No. 313. 16 The Court DENIES Zeiss’s MIL No. 4. Evidence of post-grant proceedings that Sigray 17 initiated is relevant to whether Sigray had a good-faith belief that Zeiss’s patents were invalid. In 18 other words, the evidence is relevant to whether Sigray had the specific intent to infringe the 19 asserted patents. That said, the Court agrees with Zeiss that explaining the post-grant proceedings 20 and what they mean risks confusing the jury. The parties therefore shall meet and confer to limit 21 the scope of what post-grant proceeding evidence they will present at trial.
Free access — add to your briefcase to read the full text and ask questions with AI
1 2 3 4 UNITED STATES DISTRICT COURT 5 NORTHERN DISTRICT OF CALIFORNIA 6 SAN JOSE DIVISION 7 8 CARL ZEISS X-RAY MICROSCOPY, Case No. 5:21-cv-01129-EJD INC., 9 ORDER REGARDING MOTIONS IN Plaintiff, LIMINE 10 v. 11 Re: ECF Nos. 285, 286, 296, 297, 300 SIGRAY, INC., 12 Defendant.
13 14 In advance of the Pretrial Conference scheduled for August 7, 2025, the Court issues the 15 below order regarding some of the pending motions in limine (“MIL”) to guide the discussion. 16 The parties should be prepared to discuss the remaining MILs at the Pretrial Conference: 17 • Sigray’s MIL No. 1 (ECF No. 284) 18 • Sigray’s MIL No. 4 (ECF No. 287) 19 • Zeiss’s MIL No. 1 (ECF No. 290) 20 • Zeiss’s MIL No. 2 (ECF No. 294) 21 • Zeiss’s MIL No. 5 (ECF No. 299) 22 I. SIGRAY’S MOTIONS IN LIMINE 23 A. MIL No. 2 to Exclude Evidence or Argument Regarding Three Former Xradia/Zeiss Employees 24 Sigray moves to preclude Zeiss from introducing evidence or argument regarding Sigray’s 25 hiring of three former Xradia/Zeiss employees (the “Former Employees”). ECF No. 283-3. 26 Zeiss’s amended complaint alleges that Sigray recruited from Zeiss several employees, including 27 1 the Former Employees, who had previously worked at Xradia. Sigray argues that, aside from that 2 allegation, Zeiss has neither contended nor acquired evidence that the Former Employees had any 3 part in the alleged trade secret misappropriation. Zeiss counters that evidence concerning the 4 Former Employees is relevant to its trade secret misappropriation, unfair competition, and willful 5 patent infringement claims. ECF No. 322-1. 6 The Court DENIES Sigray’s MIL No. 2. The past employment of the Former Employees 7 by Xradia and Zeiss is probative of Sigray’s access to Zeiss’s confidential information, whether 8 Sigray unfairly competed with Zeiss by gaining access to that confidential information, and 9 Sigray’s knowledge of Zeiss’s patents. Sigray has not shown that the anticipated evidence and 10 argument will overly prejudice or mislead the jury, especially given their relevance to the claims 11 and defenses in this case. To the extent Sigray still believes that the evidence Zeiss presents at 12 trial concerning the Former Employees is irrelevant to the merits of this case, Sigray may object 13 when such evidence is presented. 14 B. MIL No. 3 to Exclude Evidence or Argument of Financial Remedies Other Than Lost Profits 15 Sigray moves to preclude Zeiss from introducing evidence or argument regarding financial 16 remedies other than lost profits. ECF No. 283-4. Sigray claims that Zeiss failed to disclose the 17 calculation of reasonable royalty or unjust enrichment damages—including in Zeiss’s expert 18 reports—so Zeiss should not be allowed to pursue these remedies at trial. Zeiss appears to 19 concede that it will not pursue unjust enrichment damages but argues that it is statutorily entitled 20 to present evidence regarding a reasonable royalty as a floor for damages pursuant to 35 U.S.C. § 21 284. ECF No. 309. 22 The Court GRANTS IN PART and DENIES IN PART Sigray’s MIL No. 3. Zeiss does 23 not oppose the MIL as to unjust enrichment damages, so it may not pursue that remedy at trial. 24 However, Zeiss may present evidence concerning a reasonable royalty. The Federal Circuit has 25 made clear that, when infringement is found, courts must award at least reasonable royalty 26 damages. Dow Chem. Co. v. Mee Indus., Inc., 341 F.3d 1370, 1381 (Fed. Cir. 2003). 27 1 Accordingly, even if the jury rejects Zeiss’s expert testimony on lost profits, the jury may still 2 consider the evidence presented to determine damages on a reasonable royalty basis. To that end, 3 the parties shall meet and confer as to what kind of reasonable royalty evidence Zeiss intends to 4 use and how it will be presented. 5 II. ZEISS’S MOTIONS IN LIMINE 6 A. MIL No. 3 to Exclude Witness Testimony Regarding Non-Infringing Alternatives 7 Zeiss seeks to preclude (1) lay witness testimony, including that of Ms. Sylvia Lewis, 8 regarding non-infringing alternatives, and (2) testimony by Sigray’s damages expert, David 9 Hanson, regarding an allegedly non-infringing alternative to the accused Eclipse product called the 10 “No Sample Y Motion Redesign.” ECF No. 295-3. Zeiss argues that, as a lay witness, Lewis may 11 not testify as to whether any alleged alternative is non-infringing. ECF No. 314-2. Zeiss also 12 contends that Hanson’s opinion concerning the No Sample Y Motion Redesign lacks foundation 13 because he relied on a conversation he had with Lewis and is untimely because he could have 14 disclosed the No Sample Y Motion Redesign earlier. Id. 15 The Court DENIES Zeiss’s MIL No. 3. Lewis may testify about the structure, operation, 16 and implementation of the No Sample Y Motion Redesign. As Sigray’s president, Lewis is 17 competent to testify about these facts because Sigray sells its Apex device, which already 18 implements the No Sample Y Motion Redesign. However, Lewis may not go further to opine that 19 the No Sample Y Motion Redesign does not infringe the patents at issue in this case. See Fed. R. 20 Evid. 701. 21 The Court will also allow Hanson to testify that the No Sample Y Motion Redesign is a 22 non-infringing alternative. Hanson’s disclosure of the No Sample Y Motion Redesign was timely 23 because Sigray’s Eclipse product was not a part of this case until a few months prior to the 24 disclosure. In 2023, Zeiss’s technical and damages expert reports only addressed Sigray’s 25 TriLambda and Prisma products. Zeiss began accusing the Eclipse product in February 2025, 26 when Zeiss served supplemental expert reports. Hanson responded to those supplemental reports 27 1 with his own report in May 2025, in which he opined that the No Sample Y Motion Redesign is a 2 non-infringing alternative to the Eclipse product. Furthermore, Hanson’s opinion does not lack 3 foundation. He may properly rely on testimony from lay witnesses, like Lewis, to form his 4 opinions. See Fed. R. Evid. 703 (“[an] expert may base an opinion on facts or data in the case that 5 the expert has been made aware of or personally observed.”). To the extent Zeiss contests the 6 weight and basis of Hanson’s opinion, Zeiss may cross examine Hanson at trial. 7 B. MIL No. 4 to Exclude Evidence or Argument Regarding Post-Grant Proceedings 8 Zeiss moves to exclude evidence, testimony, and argument regarding any post-grant 9 proceedings, including inter partes review and ex parte reexamination, on the patents asserted in 10 this case. ECF No. 297. Zeiss argues that these post-grant proceedings are irrelevant because 11 invalidity is no longer an issue in this litigation. Further, Zeiss contends that such evidence will 12 confuse the jury and waste time, because the parties will be required to explain and contextualize 13 the post-grant proceedings to the jury. Sigray opposes Zeiss’s motion and claims that the post- 14 grant proceedings are highly probative of whether Sigray infringed Zeiss’s patents willfully. ECF 15 No. 313. 16 The Court DENIES Zeiss’s MIL No. 4. Evidence of post-grant proceedings that Sigray 17 initiated is relevant to whether Sigray had a good-faith belief that Zeiss’s patents were invalid. In 18 other words, the evidence is relevant to whether Sigray had the specific intent to infringe the 19 asserted patents. That said, the Court agrees with Zeiss that explaining the post-grant proceedings 20 and what they mean risks confusing the jury. The parties therefore shall meet and confer to limit 21 the scope of what post-grant proceeding evidence they will present at trial. Such evidence should 22 be limited to only what is necessary to aid the jury in determining Sigray’s willfulness. 23 C. MIL No. 6 to Exclude Testimony or Argument Regarding Zeiss’s Motives for 24 Filing This Suit 25 Zeiss seeks to exclude testimony or argument that it used the existence of the instant 26 lawsuit for competitive advantage in its sales efforts against Sigray. ECF No. 300. Sigray 27 responds that if Zeiss attempts to characterize its own motives for filing this suit, Sigray should be 1 allowed to rebut that characterization and respond in kind. ECF No. 311-1. 2 The Court GRANTS Zeiss’s MIL No. 6. Neither side shall make any argument about 3 || Zeiss’s reason for filing this lawsuit. Such argument is wholly irrelevant to the merits of the 4 || parties’ claims and defenses and is highly likely to prejudice the jury. If either party attempts to 5 make those arguments at trial, the opposing party may object. 6 7 IT IS SO ORDERED. 8 Dated: July 6, 2025 9 10 EDWARD J. DAVILA 11 United States District Judge a 12
15 16
it
4 18 19 20 21 22 23 24 25 26 27 28 || Case No.: 5:21-cv-01129-EJD ORDER REGARDING MOTIONS IN LIMINE